adecatumumab adecatumumab adecatumumab (mt201) is a recombinant human igg1 monoclonal antibody which is used to target tumor cells. it binds to the epithelial cell adhesion molecule (epcam - cd326), with the intent to trigger antibody-dependent cellular cytotoxicity. it was developed by micromet inc, which was acquired by amgen. adecatumumabmonoclonal antibodytypewhole antibodysourcehumantargetepcamclinical dataatc codenoneidentifierscas number503605-66-1 nchemspidernoneunii000705zasdchemical and physical dataformulac6552h10080n1740o2052s46molar mass147533.60 g·mol−1 ny (what is this?) (verify) adecatumumab has been used in clinical studies of treatment in colorectal, prostate and breast cancers. phase ii results were published in 2010.